REVA Announces Stopping Trading on Australian Stock Exchange: RVA.AX

SAN DIEGO, February 17, 2019 (GLOBE NEWSWIRE) – REVA Medical, Inc. (ASX: RVA) ("REVA" or the "Company") announced today that on February 18, 2019 (AEDT), the Australian Stock Exchange of securities a market announcement stating that the securities of the Company were put on hold pending trading at our request until the end of the trading on February 19, 2019. The stop trading request has was conducted in accordance with ASX Rule 17.1, while the Company has discussions with representatives of certain of its major debt and equity holders in an attempt to meet the immediate financing needs of the Company.

About REVA Medical
REVA Medical is a medical device company specializing in the development and commercialization of bioabsorbable polymer technologies for vascular applications. The company's products include the Fantom Encore and MOTIV bioabsorbable vascular scaffolds, respectively, for the treatment of coronary artery disease and peripheral arterial disease below the knee. REVA currently sells Fantom Encore in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy and Turkey, and currently markets Fantom Encore in seven other countries. REVA is based in San Diego, California.

Fantom, Fantom Encore, MOTIV and Tyrocore are trademarks of REVA Medical, Inc.

Forward-looking statements
This announcement contains or may contain forward-looking statements that are based on the beliefs, badumptions and expectations of management and the information currently available to management. All statements that are not statements of historical fact, including statements about future plans or results of operations, as well as events or developments that may occur in the future, are forward-looking statements, such as statements regarding projections and timing of commercial transactions. Sales, Clinical Trials, Pipeline Product Development and Future Financing. You should not place undue reliance on forward-looking statements. Although management believes that forward-looking statements are reasonable as and when they are made, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed in the statements. forward-looking statements, including the risks and uncertainties described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission ("SEC") on March 7 2018, and updated in our periodic reports thereafter. The forward-looking statements contained in this announcement speak only as of the date they were made. REVA does not badume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.